VCIM
EPRX

Velan Capital Investment Management’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Velan Capital Investment Management’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.33M Hold
352,000
– – 1.42% 17
2026
Q1 		$2.55M Hold
352,000
– – 1.6% 16
2025
Q4 		$2.66M Hold
352,000
– – 1.54% 20
2025
Q3 		$2.08M Buy
+352,000
New +$1.92M 1.95% 15

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Velan Capital Investment Management's EPRX Position: Q2 2026 in Review

Velan Capital Investment Management held its Eupraxia Pharmaceuticals (EPRX) position steady in Q2 2026 at 352,000 shares worth $2.33M. The position accounts for 1.42% of the portfolio, ranked #17.

Velan Capital Investment Management first reported a position in EPRX in Q3 2025 and has held it in 4 quarters since. The position peaked at $2.66M in Q4 2025. 67 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

  • Velan Capital Investment Management held 352,000 shares of Eupraxia Pharmaceuticals worth $2.33M as of Q2 2026.
  • Velan Capital Investment Management left its Eupraxia Pharmaceuticals share count unchanged in Q2 2026.
  • Eupraxia Pharmaceuticals made up 1.42% of Velan Capital Investment Management's portfolio in Q2 2026, its #17 holding.
  • Velan Capital Investment Management first reported a position in Eupraxia Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Velan Capital Investment Management's Eupraxia Pharmaceuticals position peaked at $2.66M in Q4 2025.
  • 67 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Velan Capital Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.